Meeting
2022 ASCO Annual Meeting
Artificial intelligence (AI)–powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of response to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC).
Authors
Hee Jin Lee
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Hee Jin Lee , Soo Yoon Cho , Eun Yoon Cho , Yoojoo Lim , Soo Ick Cho , Wonkyung Jung , Sanghoon Song , Mingu Kang , Jeongun Ryu , Minuk Ma , Seonwook Park , Kyunghyun Paeng , Chan-Young Ock , Sang Yong Song , Gyungyub Gong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 595)
DOI
10.1200/JCO.2022.40.16_suppl.595
Abstract #
595
Poster Bd #
366
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Collaborative federated learning behind hospitals’ firewalls for predicting histological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
First Author: Jean Ogier du Terrail
Poster
2020 ASCO Virtual Scientific Program
Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC).
First Author: Clinton Yam
Poster
2019 ASCO Annual Meeting
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
First Author: Maryann J. Kwa
Poster
2018 ASCO Annual Meeting
Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial.
First Author: Cornelia Liedtke